Nano dot technology enters clinical trials.

Journal of the National Cancer Institute

Volumn 103, Issue 19, 2011, Pages 1428-1429

  Friedman, Roberta ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; APREPITANT; DRUG CARRIER; GOLD; MACROGOL DERIVATIVE; MORPHOLINE DERIVATIVE; NANOPARTICLE; SILICON DIOXIDE;

ANIMAL; CHEMICALLY INDUCED DISORDER; CHEMISTRY; CLINICAL TRIAL (TOPIC); COLLOID; DISEASE MODEL; EXPERIMENTAL MELANOMA; HUMAN; NANOTECHNOLOGY; NAUSEA; NEOPLASM; NOTE;

ANIMALS; ANTIEMETICS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; COLLOIDS; DISEASE MODELS, ANIMAL; DRUG CARRIERS; GOLD; HUMANS; MELANOMA, EXPERIMENTAL; MORPHOLINES; NANOPARTICLES; NANOTECHNOLOGY; NAUSEA; NEOPLASMS; POLYETHYLENE GLYCOLS; SILICON DIOXIDE;

EID: 80855161019     PISSN: None     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djr400     Document Type: Note

References (0)